Cargando…

Macrophage-derived exosomes attenuate fibrosis in airway epithelial cells through delivery of antifibrotic miR-142-3p

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease of unknown aetiology and cure. Recent studies have reported a dysregulation of exosomal microRNAs (miRs) in the IPF context. However, the impact of IPF-related exosomal miRs on the progression of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guiot, Julien, Cambier, Maureen, Boeckx, Amandine, Henket, Monique, Nivelles, Olivier, Gester, Fanny, Louis, Edouard, Malaise, Michel, Dequiedt, Franck, Louis, Renaud, Struman, Ingrid, Njock, Makon-Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509395/ https://www.ncbi.nlm.nih.gov/pubmed/32759383 http://dx.doi.org/10.1136/thoraxjnl-2019-214077

Ejemplares similares

Sputum exosomes: promising biomarkers for idiopathic pulmonary fibrosis
por: Njock, Makon-Sébastien, et al.
Publicado: (2019)

Systematic review of overlapping microRNA patterns in COVID-19 and idiopathic pulmonary fibrosis
por: Guiot, Julien, et al.
Publicado: (2023)

A Blood Exosomal miRNA Signature in Acute Respiratory Distress Syndrome
por: Parzibut, Gilles, et al.
Publicado: (2021)

Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets
por: Guiot, Julien, et al.
Publicado: (2019)

Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction
por: Guiot, Julien, et al.
Publicado: (2021)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Endothelial extracellular vesicles promote tumour growth by tumour‐associated macrophage reprogramming
por: Njock, Makon‐Sébastien, et al.
Publicado: (2022)

A new nucleosomic-based model to identify and diagnose SSc-ILD
por: Guiot, Julien, et al.
Publicado: (2020)

Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ?
por: Guiot, Julien, et al.
Publicado: (2022)

Exosomal Long Non-Coding RNAs in Lung Diseases
por: Poulet, Christophe, et al.
Publicado: (2020)

Sorting and packaging of RNA into extracellular vesicles shape intracellular transcript levels
por: O’Grady, Tina, et al.
Publicado: (2022)

Airflow obstruction as a marker of adverse prognosis in rheumatoid arthritis
por: Guiot, Julien, et al.
Publicado: (2023)

Increased KL-6 levels in moderate to severe COVID-19 infection
por: Cambier, Maureen, et al.
Publicado: (2022)

Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature
por: Bonhomme, Olivier, et al.
Publicado: (2019)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
por: Liang, Minrui, et al.
Publicado: (2022)

Patient perspectives on home-spirometry in interstitial lung disease: a qualitative co-designed study
por: Mandizha, Jessica, et al.
Publicado: (2023)

The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
por: Boleto, Gonçalo, et al.
Publicado: (2022)

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
por: Wilfong, Erin M., et al.
Publicado: (2021)

Progressive fibrosing interstitial lung disease in rheumatoid arthritis: A retrospective study
por: Denis, Anna, et al.
Publicado: (2022)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis
por: Yamashita, Masahiro, et al.
Publicado: (2015)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
por: Mercer, Paul F, et al.
Publicado: (2016)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations
por: Lindell, Kathleen Oare, et al.
Publicado: (2018)

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials
por: Nathan, Steven D, et al.
Publicado: (2018)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u93fd30svub7m1d0hv9a2k54pr